Antiremodeling Effect Of Aldosterone Receptors Blockade With Canrenone In Mild Chronic Heart Failure. AREA IN-CHF Study
Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
The RALES study has shown that spironolactone reduces the risk of morbidity and mortality
both from progressive heart failure and sudden death, in patients with NYHA III or IV heart
failure. This favourable effect was clearly independent from a diuretic effect.
Antialdosterone drugs may be effective because they opposes the effects of aldosterone on
sodium retention, loss of magnesium and potassium, sympathetic activation, baroreceptor
function and vascular compliance. Antialdosterone treatment may also antagonize the effect of
aldosterone in promoting cardiac fibrosis. In a RALES substudy baseline serum PIIINP, a
marker of cardiac fibrosis synthesis showed an independent negative correlation with survival
and CHF hospitalizations in the placebo group. Therefore it seems interesting to evaluate the
effect of an Aldosterone receptor blocker on progression of left ventricular dysfunction in
patients with mild heart failure assuming standard therapy.